Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegloticase with shorter infusion duration in uncontrolled gout
NCT04511702Phase 4Completed
- Sponsor
- Amgen
- Start
- Oct 2020
- Primary completion
- Jan 2024
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of pegloticase in gout, sponsored by Amgen. Started Oct 2020; status: completed.
02
Drugs
pegloticase
03
Conditions
gout
Beyond the preview
Go deeper on NCT04511702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04511702.